Trailing Twelve Months Revenue Growth: Can-Fite (CANF)

Public company logo of canfite.com (CANF)

Can-Fite BioPharma (CANF) relies on a stable staff of R&D specialists, selectively engaging only foreign coordinators. Optimized raw material supply chains guarantee high margins for its developments. The creation of a therapy ecosystem via adenosine receptors helps treat psoriasis and liver cancer. The historical year-over-year revenue growth trend over the last 12 months demonstrates sales dynamics, where the value settled at 0.00.

Can-Fite BioPharma (CANF): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/16/2026

Can-Fite BioPharma - analytical breakdowns and key metrics (CANF)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Can-Fite BioPharma, Ltd.
Brand item of Can-Fite

Can-Fite BioPharma focuses on developing safe oral medications for the therapy of cancer and liver inflammation. This indicator captures the percentage change in revenue over a rolling year, excluding short-term market fluctuations. The investor analyzes expansion rates to assess the sustainability of the commercialization of developments. Sharp spikes in the relative growth of sales over a 12-month period compared to the previous year may signal rising credit risks. This trend reflects the actual speed of business scaling.

Who Can-Fite BioPharma competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)